MRD Monitoring by Multiparametric Flow Cytometry in AML: Is It Time to Incorporate Immune Parameters?

SIMPLE SUMMARY: Measurable residual disease (MRD) is emerging as an important prognostic and predictive biomarker in acute myeloid leukemia (AML). However, its use is currently hampered by the disparity and lack of harmonization between the available MRD methodologies. In addition, the current asses...

Descripción completa

Detalles Bibliográficos
Autores principales: Pessach, Ilias, Spyropoulos, Theodoros, Lamprianidou, Eleftheria, Kotsianidis, Ioannis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454571/
https://www.ncbi.nlm.nih.gov/pubmed/36077826
http://dx.doi.org/10.3390/cancers14174294

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454571/
https://www.ncbi.nlm.nih.gov/pubmed/36077826
http://dx.doi.org/10.3390/cancers14174294

Ejemplares similares